SCHEMBL2591422

SCHEMBL2591422

CCCOC(=O)COc1c(-c2ccc3c(c2)COC3=O)ccc(OC)c1OC

nearest known ligand 0.50

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 10/20 0.50
ABCG2 Q9UNQ0 4/20 0.45
PRF1 P14222 2/20 0.43
MAPT P10636 3/20 0.41
KDM4E B2RXH2 2/20 0.41
IMPDH2 P12268 1/20 0.41
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
ABCB1 P08183 1/20 0.40
GAA P10253 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2589066 0.94 PDE4D (0.49) PDE4DABCG2PRF1MAPTIMPDH2
SCHEMBL2591130 0.94 PDE4D (0.51) PDE4DABCG2PRF1MAPTKDM4E
SCHEMBL2587910 0.92 PDE4D (0.49) PDE4DABCG2PRF1MAPTKDM4E
SCHEMBL2593090 0.89 ABCG2 (0.48) PDE4DABCG2PRF1MAPTKDM4E
SCHEMBL2591079 0.89 PDE4D (0.50) PDE4DABCG2PRF1MAPTIMPDH2
SCHEMBL2592120 0.88 PDE4D (0.51) PDE4DABCG2PRF1KDM4EIMPDH2
SCHEMBL2589091 0.88 PDE4D (0.46) PDE4DABCG2PRF1MAPTKDM4E
SCHEMBL14734753 0.87 PRF1 (0.50) PDE4DABCG2PRF1MAPTKDM4E
SCHEMBL2588170 0.87 PDE4D (0.45) PDE4DABCG2PRF1MAPTKDM4E
SCHEMBL2591371 0.87 PDE4D (0.43) PDE4DABCG2PRF1KDM4EIMPDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 EP disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
EP-2563770-A1 BIARYL PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2013-03-06 EP disclosed
WO-2011134468-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2011-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A PDE4D 10/4885ABCG2 1085/4885PRF1 3550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.